2022
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Kim EJ, Mangold AR, DeSimone JA, Wong HK, Seminario-Vidal L, Guitart J, Appel J, Geskin L, Lain E, Korman NJ, Zeitouni N, Nikbakht N, Dawes K, Akilov O, Carter J, Shinohara M, Kuzel TM, Piette W, Bhatia N, Musiek A, Pariser D, Kim YH, Elston D, Boh E, Duvic M, Huen A, Pacheco T, Zwerner JP, Lee ST, Girardi M, Querfeld C, Bohjanen K, Olsen E, Wood GS, Rumage A, Donini O, Haulenbeek A, Schaber CJ, Straube R, Pullion C, Rook AH, Poligone B. Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides). JAMA Dermatology 2022, 158: 1031-1039. PMID: 35857290, PMCID: PMC9301595, DOI: 10.1001/jamadermatol.2022.2749.Peer-Reviewed Original ResearchConceptsT-cell lymphomaAdverse eventsHypericin-photodynamic therapyIndex lesionClinical trialsEarly-stage cutaneous T-cell lymphomaMycosis fungoides cutaneous T-cell lymphomaActive drugCommon treatment-related adverse eventsDrug-related serious adverse eventsResponse rateTreatment-related adverse eventsPhotodynamic therapyCutaneous T-cell lymphomaEnd pointLong-term adverse effectsLesion response ratePlaque-type lesionsPrimary end pointSecondary end pointsSerious adverse eventsWeeks of therapySignificant clinical responseApplication site reactionsWeeks of treatmentCorrection to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal Of Clinical Dermatology 2022, 23: 425-425. PMID: 35292936, PMCID: PMC9172872, DOI: 10.1007/s40257-022-00676-1.Peer-Reviewed Original ResearchMycosis fungoides cutaneous T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaMechlorethamine gelPROVE StudyReal-world experiencePatientsLymphomaTherapy
2021
The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal Of Clinical Dermatology 2021, 22: 407-414. PMID: 33656660, PMCID: PMC8068681, DOI: 10.1007/s40257-021-00591-x.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAgedAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleFemaleFollow-Up StudiesGelsHumansMaleMechlorethamineMiddle AgedMycosis FungoidesNeoplasm StagingProspective StudiesQuality of LifeSeverity of Illness IndexSkin NeoplasmsTreatment OutcomeUnited StatesConceptsHealth-related qualityMycosis fungoides cutaneous T-cell lymphomaCutaneous T-cell lymphomaChlormethine gelT-cell lymphomaMechlorethamine gelMonths post-treatment initiationEfficacy-evaluable patientsSkin-directed therapiesPrimary efficacy endpointProportion of patientsPatient-completed questionnairesPost-treatment initiationSkindex-29 scoresImportant therapeutic optionBody surface areaSkindex-29 questionnaireAssessment of responseReal-world studyPROVE StudyEfficacy endpointTopical corticosteroidsAdult patientsClinic visitsMycosis fungoides
2019
108 Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: results from the PROVe study
Kim E, Geskin L, Querfeld C, Girardi M, Mink D, Williams M, Angello J, Bailey W. 108 Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: results from the PROVe study. European Journal Of Cancer 2019, 119: s39. DOI: 10.1016/s0959-8049(19)30618-5.Peer-Reviewed Original ResearchMycosis fungoides cutaneous T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaQuality of lifeChlormethine gelPROVE StudyPatientsLymphomaTherapy